Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets

• Published in: Current medicinal chemistry Vol. 22; no. 27; p. 3133
• Main Authors: Dos Santos Fernandes, Guilherme Felipe, Jornada, Daniela Hartmann, de Souza, Paula Carolina, Chin, Chung Man, Pavan, Fernando Rogerio, Dos Santos, Jean Leandro
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2015
• Subjects: Animals; Antitubercular Agents - chemistry; Antitubercular Agents - pharmacology; Drug Discovery; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis - drug effects; Mycobacterium tuberculosis - metabolism; Tuberculosis - drug therapy; Tuberculosis - microbiology
• ISSN: 1875-533X
• DOI: 10.2174/0929867322666150818103836

Tuberculosis (TB) is an infectious disease caused by bacterium of the Mycobacterium genus, mainly by Mycobacterium tuberculosis (MTB). The World Health Organization aims to substantially reduce the number of cases in the coming years; however, the increased number of multidrug-resistant (MDR) and extremely drug-resistant (XDR) forms of the bacterium and the lack of treatment for latent tuberculosis are challenges to be overcome. In this review, we have identified the most potent compounds described in the literature during recent years with MIC values < 7 µM, low toxicity and a high selective index. In addition, emerging targets in MTB are presented to provide new perspectives for the discovery of new antitubercular drugs. This review aims to summarize the current advances in and promote insights into antitubercular drug discovery.